Scholars Central

Conference abstractPublished 20 Sep 2021

Bromchopulmonary dysplasia myths of pharmacologic management

Authors: Steven M. Donn

University of Michigan, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Bronchopulmonary Dysplasia is the most common long-term respiratory morbidity of preterm infants. While its pathophysiologic and histologic features have changed over time as neonatal demographics and respiratory therapies have evolved, it is now thought to be characterized by impaired distal lung growth and abnormal pulmonary microvascular development. It is believed to result from inflammatory and mechanical/oxidative injury from chronic ventilatory support in fragile, premature lungs susceptible to injury from surfactant deficiency, structural abnormalities, inadequate antioxidant defenses, and a chest wall that is more compliant than the lung. In addition, non-pulmonary issues may adversely affect lung development, including systemic infections and insufficient nutrition. Once BPD has developed, its management often involves treatment with a wide variety of agents despite an alarming lack of evidence for either safety or efficacy, including anti-inflammatories, diuretics, steroids, pulmonary vasodilators, antioxidants, and molecules involved in the cell signaling cascade.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Steven M. Donn”